Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The development marks a significant step in integrating artificial intelligence and robotics into pharmaceutical production, with implications for manufacturing efficiency, regulatory compliance, and the broader contract development and manufacturing organization (CDMO) landscape.
The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring, and autonomous materials movement. By combining PDAOAI with TechForce’s autonomous robotic systems, the integrated platform aims to support intelligent pharmaceutical manufacturing and create potential opportunities in software licensing, automation deployment, manufacturing partnerships, and technology-enabled CDMO services.
“This milestone demonstrates our commitment to leveraging advanced technologies to transform pharmaceutical manufacturing,” said Dr. Vuong Trieu, CEO of Oncotelic, who has filed over 500 patent applications and holds 75 issued patents. The company plans to showcase the platform at the BIO International Convention 2026 in San Diego, signaling its intent to pursue broader commercialization within the pharmaceutical manufacturing sector.
The importance of this announcement lies in its potential to address critical challenges in drug manufacturing, including quality control, operational efficiency, and cost reduction. AI-powered GMP platforms can enhance consistency in sterile injectable production, reduce human error, and improve regulatory compliance through real-time monitoring and automated record-keeping. For an industry facing increasing pressure to accelerate drug development and manufacturing timelines while maintaining stringent quality standards, such innovations could offer a competitive edge.
For Oncotelic, the initiative aligns with its broader strategy of leveraging its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. The company is a clinical-stage biopharmaceutical firm focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. Beyond its internal pipeline, Oncotelic licenses and co-develops drug candidates through strategic partnerships and joint ventures, including its 45% stake in GMP Bio.
The implications for the pharmaceutical industry are substantial. If successful, the platform could enable smaller biotech firms to access advanced manufacturing capabilities without heavy capital investments, potentially accelerating the development of novel therapies. For contract manufacturers, AI-driven automation could lead to faster turnaround times, higher yields, and reduced contamination risks. Investors and industry observers will be watching for further updates, particularly the demonstration at the BIO International Convention 2026, which could attract partnerships and licensing deals.
More information about the company’s latest news and updates is available at https://nnw.fm/OTLC. The full press release is accessible at https://nnw.fm/j1n43.
